US 11,673,930 B2
IL10 agonists and methods of use thereof
Jie Dai, Yorktown Heights, NY (US); Maria del Pilar Molina-Portela, Bronx, NY (US); Ella Ioffe, Bronx, NY (US); and Markus Mohrs, Pleasantville, NY (US)
Assigned to Regeneran Pharmaceuticals, Inc., Tarrytown, NY (US)
Filed by Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US)
Filed on May 11, 2021, as Appl. No. 17/317,475.
Claims priority of provisional application 63/023,703, filed on May 12, 2020.
Prior Publication US 2021/0355184 A1, Nov. 18, 2021
Int. Cl. A61K 38/20 (2006.01); A61K 47/68 (2017.01); C07K 14/54 (2006.01); C07K 19/00 (2006.01); A61P 35/00 (2006.01); C07K 1/22 (2006.01); C07K 16/42 (2006.01); A61K 38/00 (2006.01)
CPC C07K 14/5428 (2013.01) [A61K 38/2066 (2013.01); A61K 47/68 (2017.08); A61K 47/6889 (2017.08); A61P 35/00 (2018.01); C07K 1/22 (2013.01); C07K 16/42 (2013.01); A61K 38/00 (2013.01); C07K 2317/524 (2013.01); C07K 2317/526 (2013.01); C07K 2317/53 (2013.01); C07K 2319/30 (2013.01)] 24 Claims
OG exemplary drawing
 
1. A method of treating a solid tumor resistant to treatment with an anti-PD1 antibody, the method comprising administering to a subject in need thereof an IL10 agonist comprising, from amino to carboxy terminus:
(a) an IgG Fc domain;
(b) a linker moiety; and
(c) an IL10 moiety.